NMTR Stock Overview
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders.
9 Meters Biopharma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.21|
|52 Week High||US$1.43|
|52 Week Low||US$0.20|
|1 Month Change||-18.84%|
|3 Month Change||-4.40%|
|1 Year Change||-83.33%|
|3 Year Change||-78.92%|
|5 Year Change||n/a|
|Change since IPO||-96.29%|
Recent News & Updates
9 Meters Biopharma GAAP EPS of -$0.04 in-line
9 Meters Biopharma press release (NASDAQ:NMTR): Q2 GAAP EPS of -$0.04 in-line. As of June 30, 2022, the company's cash and cash equivalents totaled approximately $29.5M, compared to approximately $37.2M as of March 31, 2022.
|NMTR||US Pharmaceuticals||US Market|
Return vs Industry: NMTR underperformed the US Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: NMTR underperformed the US Market which returned -23.2% over the past year.
|NMTR Average Weekly Movement||11.1%|
|Pharmaceuticals Industry Average Movement||11.3%|
|Market Average Movement||6.8%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: NMTR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: NMTR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications.
9 Meters Biopharma Fundamentals Summary
|NMTR fundamental statistics|
Is NMTR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NMTR income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.18|
|Net Profit Margin||0.00%|
How did NMTR perform over the long term?See historical performance and comparison
Is NMTR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NMTR?
Other financial metrics that can be useful for relative valuation.
|What is NMTR's n/a Ratio?|
Price to Book Ratio vs Peers
How does NMTR's PB Ratio compare to its peers?
|NMTR PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
SHWZ Medicine Man Technologies
OPNT Opiant Pharmaceuticals
ETON Eton Pharmaceuticals
NMTR 9 Meters Biopharma
Price-To-Book vs Peers: NMTR is good value based on its Price-To-Book Ratio (2.5x) compared to the peer average (11.8x).
Price to Earnings Ratio vs Industry
How does NMTR's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Book vs Industry: NMTR is expensive based on its Price-To-Book Ratio (2.5x) compared to the US Pharmaceuticals industry average (1.7x)
Price to Book Ratio vs Fair Ratio
What is NMTR's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||2.5x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate NMTR's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of NMTR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: NMTR ($0.22) is trading below our estimate of fair value ($42.73)
Significantly Below Fair Value: NMTR is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is 9 Meters Biopharma forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NMTR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NMTR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NMTR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NMTR is forecast to have no revenue next year.
High Growth Revenue: NMTR is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NMTR's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has 9 Meters Biopharma performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NMTR is currently unprofitable.
Growing Profit Margin: NMTR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NMTR is unprofitable, and losses have increased over the past 5 years at a rate of 24% per year.
Accelerating Growth: Unable to compare NMTR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NMTR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).
Return on Equity
High ROE: NMTR has a negative Return on Equity (-206.37%), as it is currently unprofitable.
Discover strong past performing companies
How is 9 Meters Biopharma's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: NMTR's short term assets ($31.3M) exceed its short term liabilities ($9.3M).
Long Term Liabilities: NMTR's short term assets ($31.3M) exceed its long term liabilities ($83.2K).
Debt to Equity History and Analysis
Debt Level: NMTR is debt free.
Reducing Debt: NMTR currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NMTR has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: NMTR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 31.4% each year
Discover healthy companies
What is 9 Meters Biopharma current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|9 Meters Biopharma Dividend Yield vs Market|
|Company (9 Meters Biopharma)||n/a|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||4.7%|
|Industry Average (Pharmaceuticals)||2.6%|
|Analyst forecast in 3 Years (9 Meters Biopharma)||n/a|
Notable Dividend: Unable to evaluate NMTR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NMTR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NMTR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NMTR's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NMTR has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Temperato (57 yo)
Mr. John Temperato has been President, Chief Executive Officer and Director at 9 Meters Biopharma Inc. (formerly known as 9 Meters Biopharma, Inc.) since April 30, 2020. Mr. Temperato served as Chief Execu...
CEO Compensation Analysis
|John Temperato's Compensation vs 9 Meters Biopharma Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$2m||US$537k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$2m||US$329k|
Compensation vs Market: John's total compensation ($USD2.19M) is above average for companies of similar size in the US market ($USD784.47K).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
Experienced Management: NMTR's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Experienced Board: NMTR's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: NMTR insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|06 Jul 22||BuyUS$28,463||John Temperato||Individual||125,000||US$0.23|
|01 Jul 22||SellUS$912,662||OrbiMed Advisors LLC||Company||2,995,601||US$0.56|
|23 May 22||BuyUS$7,608||Michael Constantino||Individual||16,000||US$0.48|
|18 May 22||BuyUS$50,000||Mark Sirgo||Individual||106,383||US$0.47|
|18 May 22||BuyUS$22,285||John Temperato||Individual||50,000||US$0.45|
|03 Mar 22||BuyUS$55,590||John Temperato||Individual||100,000||US$0.56|
|03 Mar 22||BuyUS$50,002||Mark Sirgo||Individual||86,449.55||US$0.58|
|02 Dec 21||BuyUS$44,500||Mark Sirgo||Individual||50,000||US$0.89|
|18 Nov 21||BuyUS$52,500||John Temperato||Individual||50,000||US$1.05|
|18 Nov 21||BuyUS$21,200||Mark Sirgo||Individual||20,000||US$1.06|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
9 Meters Biopharma, Inc.'s employee growth, exchange listings and data sources
- Name: 9 Meters Biopharma, Inc.
- Ticker: NMTR
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$55.708m
- Shares outstanding: 259.11m
- Website: https://www.9meters.com
Number of Employees
- 9 Meters Biopharma, Inc.
- 8480 Honeycutt Road
- Suite 120
- North Carolina
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NMTR||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Jan 2018|
|2Q3||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 2018|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/02 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.